Recent promising experimental studies have focused on targeting the hypoxic tumour environment as well as improved anti-PD-L1 efficacy with specifically developed nanoparticles to improve the efficacy of (immune-RT [77,78]. The gene discussed is CD274; the disease is neoplasm.